Clinical trials: Strokes Thrombotic
Cerebral Small Vessel Diseases, Stroke, Lacunar
LACunar Intervention (LACI-2) Trial-2
About 35,000 people each year in the UK have a type of stroke, called 'lacunar' or 'small vessel' stroke, which is different to other common types of stroke and for which there is no proven treatment.
- Trial name
- LACI-2 (NCT03451591)
- Testing
- Isosorbide Mononitrate XL (ISMN), Cilostazol, ISMN XL and Cilostazol
- Where
- United Kingdom
- Volunteers
- 363 people
- Sponsor
- University of Edinburgh
End Stage Renal Disease Requiring Hemodialysis
Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug
Patients whose kidneys are no longer able to work as they should and require treatment to filter wastes from the blood (hemodialysis) are at high risk for blood clots that form in blood vessels (thrombosis) blocking blood flow…
- Trial name
- RE-THINc ESRD (NCT04534114)
- Testing
- Fesomersen sodium (BAY2976217)
- Where
- 69 sites in United States, Belgium and 13 more
- Volunteers
- 307 people
- Sponsor
- Bayer
Ischemic Stroke, Thrombotic Stroke
Autonomic Neuromodulation by Transcutaneous Nerve Stimulation in Acute Ischaemic Stroke.
Autonomic modulation by transcutaneous vagal nerve stimulation in acute ischaemic stroke requiring mechanical thrombectomy: a phase IIa, sham controlled randomised trial.
- Conditions
- Ischemic Stroke, Thrombotic Stroke, Autonomic Dysfunction, Autonomic Imbalance
- Trial name
- VANS (NCT05417009)
- Testing
- trans-cutaneous auricular sensory stimulation
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- Queen Mary University of London
Stroke, Atrial Fibrillation
GLORIA-AF Registry Program - Second and Third Phases
In this part of the Registry Program patients with non-valvular atrial fibrillation (AF) at risk for stroke are enrolled to characterize the target population and to collect real world data on important outcome events.
- Trial name
- NCT01468701
- Where
- 666 sites in United States, Argentina and 19 more
- Volunteers
- 37,235 people
- Sponsor
- Boehringer Ingelheim
Stroke, Atrial Fibrillation
GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)
In this part of the Registry Program patients with non-valvular atrial fibrillation (AF) at risk for stroke are enrolled to characterize the target population and to collect real world data on important outcome events.
- Trial name
- NCT01671007
- Where
- 522 sites in Austria, Belgium and 20 more
- Volunteers
- 10,471 people
- Sponsor
- Boehringer Ingelheim
Acute Ischemic Stroke, Thrombotic Disease
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
This is a Phase 1b/2, double-blind (study participants and Investigators), placebo-controlled, randomized, single-ascending dose, multi-center study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics…
- Trial name
- ASSENT (NCT02586233)
- Testing
- DS-1040b
- Where
- 55 sites in United States, Australia and 9 more
- Volunteers
- 106 people
- Sponsor
- Daiichi Sankyo
Myocardial Infarction, Cardiovascular Death
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).
- Conditions
- Myocardial Infarction, Cardiovascular Death, Atherothrombosis, Stroke
- Trial name
- PEGASUS (NCT01225562)
- Testing
- Ticagrelor 90 mg, Ticagrelor 60 mg
- Where
- 826 sites in United States, Argentina and 29 more
- Volunteers
- 21,379 people
- Sponsor
- AstraZeneca